Immune Evasion Articles & Analysis: Older
5 news found
NextPoint’s programs aim to deliver monotherapies for cancer patients without viable treatment options. While immune checkpoint inhibitors targeting PD-1/L1 have revolutionized cancer treatments, many patients do not benefit from these medications and require novel therapeutic strategies. ...
ByBayer AG
PHILADELPHIA, Dec. 08, 2022 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or the “Company”) (Nasdaq: CNTX), a women’s oncology company developing novel treatments for breast and gynecologic cancers, announced preliminary Phase 2 data from the ongoing SMILE trial of onapristone extended release (ONA-XR), the company’s novel, first-in-class, potent, ...
In solid tumors, activation of LILRB2 by its ligands, including HLA-G, ANGPTLs, SEMA4A, and CD1d, induces a tolerogenic phenotype in myeloid cells, thereby suppressing T cell activation and promoting tumor immune evasion. ABOUT IO-108 IO-108 binds to LILRB2 with high affinity and specificity and blocks the interaction of LILRB2 with multiple ligands that are ...
In mRNA vaccines, the unnatural RNA nucleobase N1-methylpseudoUridine can enhance immune evasion and protein production. N1-methylpseudoUridine from BOC Sciences has been contributing to the current production of COVID-19 mRNA vaccines. ...
Wellems' major areas of research are drug responses, immune evasion, and disease mechanisms in malaria. His specific interests include antimalarial drug resistance and determinants of clinical outcome after treatment, malaria protection conferred by human hemoglobinopathies and red cell polymorphisms, antigenic variation and immune ...